HOME  | CONTACT  | PATIENT LOGIN  | CLINIC LOGIN  | FAQ
  • PATIENTS &
    HEALTHY VOLUNTEERS
  • INVESTIGATORS
  • CROS / SPONSORS
  • CAREERS
  • TRIAL ALERTS

TRIALS SEARCH
      
  • HEALTH NEWS

  • RSS FEEDS

  • ABOUT TRIALS

  • LINK TO US


View Clinical Trial (Medical Research Study)


IV Lacosamide: The Safety of Intravenous Lacosamide

Signup
Browse Studies

City:   Memphis
State:   Tennessee
Zip Code:   38103
Conditions:   Epilepsy
Purpose:   To evaluate the safety of IV Lacosamide in children with partial-onset epilepsy, ages 4-20 years old, inclusive, who are either unable to take oral medication or require intravenous administration of IV Lacosamide.
Study Summary:   Lacosamide tablets and intravenous formulations were both approved in the United States in the fall of 2008. Lacosamide is indicated for use as adjunctive therapy in the treatment of partial onset seizure disorder in patients' age seventeen years and older. A parenteral dosage form of Lacosamide is desirable for patients who are temporarily unable to take medication orally. The objective of this study is to evaluate the safety of IV Lacosamide in children with epilepsy, ages 4 to 20 years, who are either unable to take oral medication, or whom parenteral administration of IV Lacosamide is desirable.
Criteria:   Inclusion Criteria - Patients must have a diagnosis of epilepsy and have received anti-epileptic drug therapy prior to initiation of IV Lacosamide - Patients must have a medial condition in which the parenteral administration of Lacosamide is desirable. - Patients may be male or female. - Patients must be 4 years of age or older, and less than age 20 years. - Patient or his / her legally authorized representative must sign an informed consent form prior to any study specific procedures. Exclusion Criteria Patients will be excluded from entry into the study if any of the following are true: - Patient has previously participated in any other intravenous Lacosamide study. - Patient has status epilepticus within the last 3 months. - Patient has a history of drug allergy to Lacosamide. - Patient is pregnant. - Patient has taken experimental drug within last 30 days. - Patient with significant hepatic or renal disease.
NCT ID:   NCT00832884
Primary Contact:   Principal Investigator
James W Wheless, MD
LeBonheur Children's Medical Center

Michelle J Ellis, RN, CCRP
Phone: 901-287-5330
Email: Michelle.Ellis@lebonheur.org
Backup Contact:   N/A
Location Contact:   Memphis, Tennessee 38103
United States

Michelle J Ellis, RN
Phone: 901-287-5330
Email: Michelle.Ellis@lebonheur.org

Site Status: Recruiting

Click here to see:
  • Clinical trials for Epilepsy in Memphis, Tennessee

Data Source:   ClinicalTrials.gov
Date Processed:   May 25, 2013
Modifications to this listing:   Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


If you would like to be contacted by the clinical trial representative please enter your contact information, then click "I Am Interested In This Study"
First Name:  
Last Name:  
Email Address:  
Confirm Email:    
Daytime Phone (eg. 555-555-5555):  
City:  
State:
Zip Code:    
Best Time to Call:  
Questions/Comments:  
  • NEARBY STUDIES

Within 25 Miles

Pediatric Depression - Memphis TN

Irritable Bowel Syndrome (with diarrhea) - Memphis TN

Anti-Depressant Induced Sexual Dysfunction - Memphis TN

Obsessive Compulsive Disorder (OCD) - Memphis TN

Uncontrolled Angina (Adult Stem Cell Research) - Germantown TN

Within 50 Miles

Within 100 Miles

 
Clinical Connections Home | Investigators | CROs / Sponsors | Clinical Trials Notification | Search Clinical Trials | About Clinical Trials | Links | Terms And Conditions | Sitemap | Suggestions / Feedback
© 1998-2013 | All trademarks are property of their legal owners. | All Rights Reserved

ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted worldwide.

ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.